Halozyme Therapeutics HALO Common stock, shares issued (in shares)
Common stock, shares issued (in shares) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's common stock, shares issued (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's common stock, shares issued (in shares)?
- Halozyme Therapeutics (HALO) reported common stock, shares issued (in shares) of $118.52M in Q1 2026.
- How has Halozyme Therapeutics's common stock, shares issued (in shares) changed year-over-year?
- Halozyme Therapeutics's common stock, shares issued (in shares) decreased by 3.8% year-over-year, from $123.17M to $118.52M.
- What is the long-term trend for Halozyme Therapeutics's common stock, shares issued (in shares)?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's common stock, shares issued (in shares) has grown at a -3.5% compound annual growth rate (CAGR), from $140.97M to $117.78M.